Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs

A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.

GlaxoSmithKline cozies up to Five Prime for respiratory R&D

GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover new treatments in the field.

Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late

As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

GSK taps Slaoui to chair flat-selling vaccines unit with an eye to the future

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.

GlaxoSmithKline puts emerging markets chief Hussain in charge of global pharma ops

With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too.

Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up

GlaxoSmithKline said today it is considering a spinoff of ViiV, the successful HIV-centric business it shares with Pfizer and Shionogi. Its talk of unlocking the "intrinsic" value of the business mirrored the language a hedge fund investor used hours earlier to suggest that Amgen do much the same thing, breaking into two companies, one for legacy drugs and one for new launches.

GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots

With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too.

Advair sales slide triggers another $1.6B in cost cuts at GlaxoSmithKline

Brace yourselves for layoffs at GlaxoSmithKline. The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate. This time, the faltering drug is Advair, which adds some new twists to the story--including a warning to the whole pharma industry about formulary placement.

GlaxoSmithKline weighs an IPO for HIV-focused ViiV as it sharpens the budget ax

GlaxoSmithKline is considering taking its HIV joint venture public, tersely dropping hints of an IPO for ViiV Healthcare as it lays out plans to again slash R&D costs and refocus its business.

GSK exec stresses need to move away from 'fragmented' approach to drug delivery

Talking of breaking internal siloes has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKlines' head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference.